Valuation: BLS Pharmaceuticals Limited

Market Cap 242M 168M 148M 140M 127M 239M 16.12B 1.68B 646M 8.24B 631M 618M 26.43B P/E 2025
17.8x
P/E 2026 13.9x
Enterprise Value 237M 165M 145M 137M 124M 234M 15.8B 1.64B 633M 8.08B 619M 605M 25.9B EV / Sales 2025
2.82x
EV / Sales 2026 2.82x
Free-Float
41.59%
Yield 2025 *
-
Yield 2026 -
1 day+5.53%
1 week-11.02%
Current month-0.94%
1 month+14.13%
3 months+11.70%
6 months+75.00%
Current year+150.00%
1 week 0.94
Extreme 0.945
1.15
1 month 0.93
Extreme 0.93
1.3
Current year 0.36
Extreme 0.36
1.3
1 year 0.33
Extreme 0.33
1.3
3 years 0.04
Extreme 0.04
1.3
5 years 0.04
Extreme 0.04
1.3
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 18/05/2023
Director of Finance/CFO 72 31/08/2016
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 04/12/2012
Director/Board Member 72 29/06/2022
Director/Board Member - 18/05/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Buy 5,000,000 0.2202%
14/05/26 Exercice 5,000,000 0.2202%
22/03/26 Buy

Chief Executive Officer

1,800,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
+5.53%-11.02%+169.23%+650.00% 160M
+4.16%-0.30%+58.96%+94.17% 71.53B
-0.19%+1.32%+37.20%+81.33% 60.12B
-1.51%+2.39%+9.10%+36.79% 48.85B
+0.58%+0.90%+42.29%+39.40% 44.28B
+1.63%+8.74%+344.13%+692.55% 43.83B
+1.86%+1.90%+9.16%+108.36% 41.53B
-0.67%-0.45%+4.47%+46.37% 30.13B
+4.77%+6.46%+41.54%+22.78% 27.98B
+0.11%-1.75%-19.26%+358.31% 25.25B
Average +1.64%-1.14%+69.68%+213.01% 39.37B
Weighted average by Cap. +1.30%+0.62%+63.69%+155.48%

Financials

2025 2026
Net sales 29.28M 20.36M 17.93M 16.99M 15.34M 28.91M 1.95B 203M 78.22M 998M 76.46M 74.79M 3.2B 73.91M 51.4M 45.26M 42.88M 38.71M 72.97M 4.93B 513M 197M 2.52B 193M 189M 8.08B
Net income 4.9M 3.41M 3M 2.84M 2.57M 4.84M 327M 34.02M 13.09M 167M 12.8M 12.52M 536M 15.4M 10.71M 9.43M 8.93M 8.06M 15.2M 1.03B 107M 41.13M 525M 40.21M 39.33M 1.68B
Net Debt -6.13M -4.27M -3.76M -3.56M -3.21M -6.06M -409M -42.58M -16.39M -209M -16.02M -15.67M -670M -4.86M -3.38M -2.97M -2.82M -2.54M -4.79M -324M -33.71M -12.97M -166M -12.68M -12.4M -531M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
30/09/26 A$1.050 +5.53% 210,245
29/09/26 A$0.9950 -1.97% 584,377
28/09/26 A$1.015 -1.46% 817,109
25/09/26 A$1.030 -2.83% 701,683
24/09/26 A$1.060 -8.23% 1,619,547

Annual profits - Rate of surprise